Seen & Heard: Charles River Tries Not To “Freeze Out” Big Pharma Clients In China - CEO
This article was originally published in PharmAsia News
Executive Summary
A new facility that Charles River Laboratories is renovating in Shanghai has triggered overwhelming interest from the contract research organization's big pharma customers, CEO Jim Foster said March 19 during a presentation at the Lehman Brothers Healthcare conference in Miami
You may also be interested in...
Charles River Set To Launch First Global CRO Preclinical Testing Center In China
BEIJING - Charles River Laboratories, one of the world's leading contract research organizations, is set to open a new preclinical testing facility this week in the rapidly expanding Chinese market, according to Senior VP Christopher Perkins
Charles River Set To Launch First Global CRO Preclinical Testing Center In China
BEIJING - Charles River Laboratories, one of the world's leading contract research organizations, is set to open a new preclinical testing facility this week in the rapidly expanding Chinese market, according to Senior VP Christopher Perkins
Shanghai ChemPartner CEO Michael Hui On Finding A Niche In China Amidst Increasing Foreign Competition: An Interview With PharmAsia News (Part 2 of 2)
Shanghai ChemPartner was set up in 2003 at Shanghai's Zhangjiang Hi-Tech Park, and today it is one of the leading R&D outsourcing providers in China. PharmAsia News recently visited company headquarters to meet Michael Hui, CEO of ChemPartner - as well as sister company ChemExplorer, and their holding company ShangPharma - to discuss the company's recent deal with private equity investment firm TPG, as well as handling increased competition from foreign firms moving into China.